Interim Report January-March 2008 Tripep AB (publ)

• Research and development costs amounted to SEK 6.6 (3.4) million
• The loss after tax was SEK -9.9 (-6.5) million
• Earnings per share were SEK -0.16 (-0.12)
• The company had no net sales for the period
• Rights issue completed
• Patent application filed for a new antibiotic-free formulation of ChronSeal in collaboration with Kringle Pharma, Inc.
• Application filed with the Swedish Medical Products Agency for a phase II trial on ChronSeal
• Safety study on ChronSeal concluded successfully – good efficacy in acute wounds suggesting extended indication
• More information required before Tripep’s phase II trial on ChronSeal can begin
• Tripep secured a first US patent on a new type of immunotherapy against HIV-1
• Preliminary positive results in the first patient in the current ChronVac-C® study




For more information, please contact:
Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@ki.se